Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13686171 | 0.91 | BACE1 (0.36) | ELANE | |
| SCHEMBL13685011 | 0.91 | BACE1 (0.36) | ELANE | |
| SCHEMBL13685129 | 0.91 | BACE1 (0.36) | ELANE | |
| SCHEMBL13685009 | 0.88 | BACE1 (0.34) | ELANE | |
| SCHEMBL13685169 | 0.88 | BACE1 (0.34) | ELANE | |
| SCHEMBL13685651 | 0.85 | BACE1 (0.35) | ELANE | |
| SCHEMBL13685780 | 0.85 | REN (0.35) | ELANE | |
| SCHEMBL13685772 | 0.85 | REN (0.35) | ELANE | |
| SCHEMBL13685096 | 0.84 | ELANE (0.33) | ELANE | |
| SCHEMBL13685202 | 0.84 | ELANE (0.33) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | SCHERING CORPORATION | 2011-06-23 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | TMPRSS15, SPINT2, HPN | ELANE 128/4885ATM 3061/4885MEN1 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.